Amgen Submits Kineret, Enbrel sBLAs; Triangle Files Coviracil NRTI
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Amgen’s Kineret Oct. 21 sBLA for a claim to inhibit progression of structural damage in adults with moderately to severely active rheumatoid arthritis is based on a single 12-month, double-blind, placebo-controlled trial.
You may also be interested in...
Zometa two-year data "approvable"
Novartis' Zometa (zoledronic acid) sNDA to include two-year follow-up data on patients with bone metastases from advanced cancers is "approvable" Aug. 15, "pending future labeling discussions," the firm says. The long-term data comes from three pivotal trials, ranging in duration from nine to 12 months, that supported Zometa's February 2002 approval for multiple myeloma and bone metastases of solid tumors (1Pharmaceutical Approvals Monthly Nov. 1, 2002, p. 9). Novartis estimates that 500,000 patients worldwide have received Zometa...
Amgen builds structural damage claims
Amgen/Wyeth's Enbrel (etanercept) sBLA for "inhibiting the progression of structural damage of active arthritis in patients with psoriatic arthritis" clears FDA Aug. 21. Amgen's interleukin-1 receptor antagonist Kineret (anakinra) also clears FDA Aug. 22 with a supplemental indication for slowing progression of structural damage in moderately to severely active rheumatoid arthritis (1Pharmaceutical Approvals Monthly Nov. 1, 2002, p. 9)...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011